Stocks to sell

Workhorse (NASDAQ:WKHS) reported very weak first-quarter results and  appears to have no viable, strong, upcoming, positive catalysts. WKHS stock is in trouble. Source: Shutterstock The EV maker’s inability to win any major deals or recruit any impressive partners so far, its apparent failure to cash in on opportunities with the U.S. Post Office and UPS

Health insurance company Clover Health (NASDAQ:CLOV) went public via the SPAC route in January, and since then, its stock has been on a wild ride. CLOV stock became the latest target of the Reddit retail trading crowd, causing Clover’s share  price to reach new highs. Source: Shutterstock Unfortunately, the stock is now overvalued, and Clover’s

I’ve been wrong twice about DraftKings (NASDAQ:DKNG) stock. I may be again. In June 2020, six months after DraftKings came public, I warned people to look out below. At the time the stock was at $42/share. It has since traded for as much as $72/share. In January 2021 I suggested there was still time to

Clover Health (NASDAQ:CLOV) stock is up 57% in the last month. The price action highlights the uncertainty of investing in celebrity SPAC (special purpose acquisition company) plays. Source: Shutterstock Bit of background here. Venture capitalist and resident SPAC king Chamath Palihapitiya helped Clover, which sells Medicare-backed insurance plans, to go public through a $3.7 billion deal

Bionano Genomics (NASDAQ:BNGO) stock might appear interesting at first blush. After all, the company has developed an optical DNA mapping instrument called Saphyr. It is a high throughput system – which looks like a printer from the outside – that allows genome variations to be rapidly identified.  Source: Connect world / Shutterstock.com However, upon taking

MicroVision is still up for sale, just like the CEO said it was and the latest 10-Q report indicates. Unfortunately, there are still no buyers. Source: Shutterstock For some reason, the market thinks a deal will happen when the stock is at a market value of $3.41 billion. Allow me to provide an evidently-needed reality

Canoo (NASDAQ:GOEV) released its earnings on May 17 and made some concerning statements. Expect GOEV stock to drive lower. Source: Shutterstock For starters, the company is no longer going to use a contract manufacturer. It also expects to take until 2023 before electric vehicle (EV) deliveries and revenue begin to flow into the company. More troubling

There’s been plenty of talk about GameStop (NYSE:GME) stock going to the moon in 2021. At the same time, there’s been plenty of people pounding the table that the stock is overvalued. Source: Northfoto / Shutterstock.com For sure, GME stock is overvalued compared to where it was just a year ago. The stock is up

Fisker (NYSE:FSR) detailed ongoing operating and capital spending plans in its latest Q1 earnings release on May 17. A capital raise looks likely for the electric vehicle (EV) car maker, and likely to wreak havoc on FSR stock, at least until investors have visibility on when, exactly, they can expect Fisker to start producing free

Since the beginning of the year, shares of Cyprus-based shipping company Castor Maritime (NASDAQ:CTRM) stock are up by more than 80%. Source: Pavel Kapysh / Shutterstock.com As stated in its filings with the SEC back in April, its recent stock increases were “significantly inconsistent” with its performance. It continues to expand its fleet aggressively, putting

Lordstown Motors (NASDAQ:RIDE) stock, the electric car start-up, took a hard fall but then rose again on a management re-shuffle. Source: Postmodern Studio / Shutterstock.com The company admitted misstatements in demand for its Endurance pick-up. Then it accepted the resignations of CEO Steve Burns and CFO Julio Rodriguez. Becky Roof, an accountant who has been

While it may seem like “meme-stock mania” is over, several of these names are still up triple digits this year. In fact, much-maligned meme stocks are not losing steam as the more than 10 million members of Reddit’s r/WallStreetBets (WSB) community continue to push shares upward. However — as is the case with most companies

With Zomedica’s  (NYSE:ZOM) new Truforma diagnostic tool possibly facing a great deal of entrenched competition, the outlook of ZOM stock is, at best, difficult to determine. Meanwhile, the shares have a very high valuation. Source: didesign021 / Shutterstock.com A diagnostic product meant to be used by veterinarians, Truforma measures the amount of T4 and TSH

When I last wrote about Vaxart (NASDAQ:VXRT) last month I indicated that I felt that the biotech company was not worth more than about $1 per share. As of June 16, VXRT stock was at $7.67, or $1.00 higher than when I wrote about it on May 14 at $6.61. Source: Photo courtesy of Vaxart,

While Senseonics (NYSE:SENS) stock has a great deal of potential, the shares currently have a fairly high valuation. Source: Minerva Studio / Shutterstock.com Moreover, in the short-term and medium-term, SENS stock looks poised to fall significantly. Senseonics has developed Eversense, a 90-day continuous glucose monitoring (CGM) system. According to the company, the device provides continuous